Cidara Therapeutics (CDTX) News Today $21.47 -0.91 (-4.07%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$21.47 0.00 (0.00%) As of 02/21/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Cidara Therapeutics, Inc.: Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial OfficerFebruary 20 at 8:43 PM | finanznachrichten.deCidara Therapeutics appoints Karbe as CFOFebruary 19 at 4:55 AM | markets.businessinsider.comBrokerages Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) PT at $32.20February 19 at 1:13 AM | americanbankingnews.comCidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial OfficerFebruary 18, 2025 | globenewswire.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest UpdateCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 138,400 shares, a growth of 27.6% from the January 15th total of 108,500 shares. Currently, 3.0% of the company's stock are sold short. Based on an average trading volume of 90,800 shares, the short-interest ratio is currently 1.5 days.February 18, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Rating of "Buy" from AnalystsShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have earned an average recommendation of "Buy" from the six research firms that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating toFebruary 16, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Crosses Above 50-Day Moving Average - Here's What HappenedCidara Therapeutics (NASDAQ:CDTX) Stock Crosses Above 50-Day Moving Average - Time to Sell?February 14, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Upgraded at Cantor FitzgeraldCantor Fitzgerald raised Cidara Therapeutics to a "strong-buy" rating in a research report on Wednesday.February 6, 2025 | marketbeat.comCidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Increase in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 77,100 shares, an increase of 113.6% from the December 31st total of 36,100 shares. Based on an average daily volume of 65,900 shares, the days-to-cover ratio is presently 1.2 days. Currently, 1.7% of the shares of the stock are sold short.January 29, 2025 | marketbeat.comCidara Therapeutics assumed with an Overweight at Cantor FitzgeraldJanuary 28, 2025 | markets.businessinsider.comCantor Fitzgerald raises Cidara stock to OverweightJanuary 27, 2025 | msn.comCantor Fitzgerald Reiterates "Overweight" Rating for Cidara Therapeutics (NASDAQ:CDTX)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Cidara Therapeutics in a report on Monday.January 27, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Share Price Crosses Above 50 Day Moving Average - Should You Sell?Cidara Therapeutics (NASDAQ:CDTX) Stock Passes Above Fifty Day Moving Average - Here's What HappenedJanuary 22, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Given Consensus Recommendation of "Buy" by AnalystsCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) has earned a consensus rating of "Buy" from the six research firms that are presently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to thJanuary 22, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Growth in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 77,100 shares, a growth of 113.6% from the December 15th total of 36,100 shares. Approximately 1.7% of the company's stock are short sold. Based on an average trading volume of 65,900 shares, the short-interest ratio is presently 1.2 days.January 14, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Share Price Crosses Above 50-Day Moving Average - Here's What HappenedCidara Therapeutics (NASDAQ:CDTX) Share Price Passes Above 50-Day Moving Average - Time to Sell?January 9, 2025 | marketbeat.comCidara Therapeutics Inc CDTXDecember 28, 2024 | morningstar.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Decrease in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 36,100 shares, a drop of 31.6% from the November 30th total of 52,800 shares. Based on an average daily volume of 45,100 shares, the days-to-cover ratio is presently 0.8 days. Approximately 1.2% of the company's shares are sold short.December 28, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of "Buy" from AnalystsShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have been given an average recommendation of "Buy" by the six ratings firms that are currently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buyDecember 28, 2024 | marketbeat.comCidara Therapeutics files to sell 7.04M shares of common stock for holdersDecember 23, 2024 | markets.businessinsider.comTwelve option delistings on December 23rdDecember 23, 2024 | markets.businessinsider.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Growth in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the target of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 52,800 shares, a growth of 6.0% from the November 15th total of 49,800 shares. Based on an average daily trading volume, of 37,400 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.2% of the shares of the stock are short sold.December 16, 2024 | marketbeat.comRBC Capital Initiates Coverage of Cidara Therapeutics (CDTX) with Outperform RecommendationDecember 14, 2024 | msn.comCidara Therapeutics (NASDAQ:CDTX) Now Covered by Analysts at Royal Bank of CanadaRoyal Bank of Canada started coverage on Cidara Therapeutics in a report on Friday. They set an "outperform" rating and a $34.00 price objective for the company.December 13, 2024 | marketbeat.comCidara achieves full enrolment in influenza prevention trialDecember 6, 2024 | finance.yahoo.comInnovative Influenza Prevention and Strategic Moves Elevate Cidara Therapeutics’ Stock PotentialDecember 6, 2024 | markets.businessinsider.comCidara's Phase II Trial Testing CD388 For Flu Prevention Fully Enrolled With 5,000 SubjectsDecember 5, 2024 | markets.businessinsider.comCidara Therapeutics completes enrollment of Phase 2b NAVIGATE trialDecember 5, 2024 | markets.businessinsider.comRA Capital Management L.P. Acquires New Stake in Cidara Therapeutics, Inc. (NASDAQ:CDTX)RA Capital Management L.P. acquired a new stake in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 703,080 shares of the biotechnology company's stock, valued at approximatelDecember 5, 2024 | marketbeat.comCidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal InfluenzaDecember 4, 2024 | markets.businessinsider.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of "Buy" from BrokeragesCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) has been given an average rating of "Buy" by the five analysts that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendaDecember 3, 2024 | marketbeat.comCidara Therapeutics Shares Surge 26% on $105 Mln Private PlacementNovember 21, 2024 | marketwatch.comCidara Therapeutics Announces Private Placement To Raise Up To $105 Mln, Stock UpNovember 21, 2024 | markets.businessinsider.comCidara Therapeutics to issue 3.89M shares at $14.912 in private placementNovember 21, 2024 | markets.businessinsider.comCidara: Potential To Change Flu Prophylaxis Landscape With CD388November 21, 2024 | seekingalpha.comCidara Therapeutics Announces $105 Million Private PlacementNovember 21, 2024 | globenewswire.comCidara Therapeutics to Participate in Evercore 7th Annual HealthCONx ConferenceNovember 19, 2024 | globenewswire.comWhat is HC Wainwright's Estimate for CDTX FY2024 Earnings?Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - Analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Cidara Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst E. Arce now expects that the biotechnology company will earn ($8.74) pNovember 14, 2024 | marketbeat.comCidara Therapeutics’ CD388: Promising Influenza Prevention Drives Buy RatingNovember 12, 2024 | markets.businessinsider.comCidara Therapeutics (NASDAQ:CDTX) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $24.00 target price on shares of Cidara Therapeutics in a report on Monday.November 11, 2024 | marketbeat.comPositive Outlook for Cidara Therapeutics Amid Strategic Advancements and Financial StabilityNovember 9, 2024 | markets.businessinsider.comGuggenheim Initiates Coverage of Cidara Therapeutics (CDTX) with Buy RecommendationNovember 9, 2024 | msn.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Rating of "Buy" by AnalystsShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have been given a consensus rating of "Buy" by the four brokerages that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The aNovember 8, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Now Covered by GuggenheimGuggenheim assumed coverage on Cidara Therapeutics in a report on Friday. They set a "buy" rating and a $33.00 price target on the stock.November 8, 2024 | marketbeat.comCidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | globenewswire.comCidara Therapeutics to Participate in Two Upcoming November Investor ConferencesOctober 31, 2024 | globenewswire.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Drop in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 67,000 shares, a decrease of 20.0% from the September 30th total of 83,800 shares. Approximately 1.1% of the company's shares are short sold. Based on an average trading volume of 19,700 shares, the days-to-cover ratio is currently 3.4 days.October 29, 2024 | marketbeat.comPromising Results of CD388 Lead to Buy Rating for Cidara TherapeuticsOctober 23, 2024 | markets.businessinsider.comCidara Therapeutics (NASDAQ:CDTX) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $24.00 price target on shares of Cidara Therapeutics in a report on Tuesday.October 22, 2024 | marketbeat.com Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CDTX Media Mentions By Week CDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDTX News Sentiment▼0.520.60▲Average Medical News Sentiment CDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDTX Articles This Week▼62▲CDTX Articles Average Week Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Relay Therapeutics News Today Tyra Biosciences News Today AnaptysBio News Today Kura Oncology News Today CorMedix News Today Arbutus Biopharma News Today Pharming Group News Today Immatics News Today ORIC Pharmaceuticals News Today Rapport Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
